Skip to content
value.today

IRulya Therapeutics Inc.: timeline

Every dated event on file, newest first: history, results, dividends, splits, index changes, insider trades, layoffs and recalls, each with its source.

41 events

On the market-cap history; source: Market-cap history on value.today.

$302 M$890 M$1.5 B202120222023202420252026Nov 13, 2026: Results releasedOct 9, 2026: Renamed IRulya Therapeutics Inc.Sep 8, 2026: Acquisition or sale completedAug 31, 2026: Delisting noticeAug 14, 2026: Results releasedMay 17, 2026: Acquisition or sale completedApr 10, 2026: Annual report filed (Form 10-K)Mar 16, 2026: Delisting noticeFeb 12, 2026: Results releasedNov 12, 2025: Results releasedAug 11, 2025: Results releasedMay 13, 2025: Results releasedMar 24, 2025: Results releasedNov 13, 2024: Results releasedAug 30, 2024: 3 insiders bought $162,993 of shares on the marketAug 13, 2024: Results releasedDec 14, 2023: 1 insider bought $140,882 of shares on the marketNov 30, 2023: 1 insider bought $27,031 of shares on the marketAug 31, 2023: 4 insiders bought $741,105 of shares on the marketJul 21, 2023: Results releasedJan 24, 2023: Results releasedJan 24, 2023: Restructuring plan: employeesAug 1, 2022: Renamed Quince Therapeutics, Inc.Aug 1, 2022: Results releasedMay 7, 2022: Results releasedApr 26, 2022: Restructuring plan: employeesJan 28, 2022: Results releasedJan 28, 2022: Restructuring plan: employeesNov 12, 2021: 1 insider bought $10,987 of shares on the marketMar 24, 2021: 1 insider bought $3.5 million of shares on the marketJan 26, 2021: Results releasedJun 12, 2020: 2 insiders bought $2.5 million of shares on the marketJun 3, 2020: 1 insider sold $14.9 million of sharesMay 22, 2020: 2 insiders bought $3.0 million of shares on the marketMay 12, 2020: Results releasedMar 17, 2020: Results released

Point at a marker under the line to see the event. Green: good news by its nature (a raise, an index entry), orange: bad (a cut, a layoff), grey: neither.

  1. 2026

    1. Nov 13, 2026
      Results released

      Form 8-K filed 13 Nov 2026

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    2. Oct 9, 2026
      Renamed IRulya Therapeutics Inc.

      Formerly Quince Therapeutics, Inc..

      Company history · source: SEC EDGAR

    3. Sep 8, 2026
      Acquisition or sale completed

      A significant acquisition or disposal of assets was completed.

      Notable 8-K events · source: SEC EDGAR (Form 8-K)

    4. Aug 31, 2026
      Delisting notice

      The exchange told the company it no longer meets a listing rule, or the company is moving or leaving its listing (takeovers are counted separately).

      Notable 8-K events · source: SEC EDGAR (Form 8-K)

    5. Aug 14, 2026
      Results released

      Form 8-K filed 14 Aug 2026

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    6. May 17, 2026
      Acquisition or sale completed

      A significant acquisition or disposal of assets was completed.

      Notable 8-K events · source: SEC EDGAR (Form 8-K)

    7. Apr 10, 2026
      Annual report filed (Form 10-K)

      For the year to 31 Dec 2025

      Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)

    8. Mar 16, 2026
      Delisting notice

      The exchange told the company it no longer meets a listing rule, or the company is moving or leaving its listing (takeovers are counted separately).

      Notable 8-K events · source: SEC EDGAR (Form 8-K)

    9. Feb 12, 2026
      Results released

      Form 8-K filed 12 Feb 2026

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

  2. 2025

    1. Nov 12, 2025
      Results released

      Form 8-K filed 12 Nov 2025

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    2. Aug 11, 2025
      Results released

      Form 8-K filed 11 Aug 2025

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    3. May 13, 2025
      Results released

      Form 8-K filed 13 May 2025

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    4. Mar 24, 2025
      Results released

      Form 8-K filed 24 Mar 2025

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

  3. 2024

    1. Nov 13, 2024
      Results released

      Form 8-K filed 13 Nov 2024

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    2. Aug 30, 2024
      3 insiders bought $162,993 of shares on the market

      Open-market purchases between 19 Aug and 30 Aug 2024

      Insider buying and large selling · source: SEC Forms 4 and 5

    3. Aug 13, 2024
      Results released

      Form 8-K filed 13 Aug 2024

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

  4. 2023

    1. Dec 14, 2023
      1 insider bought $140,882 of shares on the market

      Open-market purchases between 01 Dec and 14 Dec 2023

      Insider buying and large selling · source: SEC Forms 4 and 5

    2. Nov 30, 2023
      1 insider bought $27,031 of shares on the market

      Open-market purchases between 29 Nov and 30 Nov 2023

      Insider buying and large selling · source: SEC Forms 4 and 5

    3. Aug 31, 2023
      4 insiders bought $741,105 of shares on the market

      Open-market purchases between 08 Aug and 31 Aug 2023

      Insider buying and large selling · source: SEC Forms 4 and 5

    4. Jul 21, 2023
      Results released

      Form 8-K filed 24 Jul 2023

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    5. Jan 24, 2023
      Results released

      Form 8-K filed 30 Jan 2023

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    6. Jan 24, 2023
      Restructuring plan: employees

      Under the Plan, the Company is reducing headcount by approximately 47% through a reduction in its workforce.

      Layoffs · source: SEC filing (8-K Item 2.05)

  5. 2022

    1. Aug 1, 2022
      Renamed Quince Therapeutics, Inc.

      Formerly Cortexyme, Inc..

      Company history · source: SEC EDGAR

    2. Aug 1, 2022
      Results released

      Form 8-K filed 01 Aug 2022

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    3. May 7, 2022
      Results released

      Form 8-K filed 12 May 2022

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    4. Apr 26, 2022
      Restructuring plan: employees

      The Company is further reducing headcount by 36%, bringing the total reduction to 67% from the January 2022 headcount levels.

      Layoffs · source: SEC filing (8-K Item 2.05)

    5. Jan 28, 2022
      Results released

      Form 8-K filed 02 Feb 2022

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    6. Jan 28, 2022
      Restructuring plan: employees

      Under the Plan, the Company is reducing headcount by approximately 53% through a reduction in its workforce.

      Layoffs · source: SEC filing (8-K Item 2.05)

Share price moves are worked out where the site has the listing's daily prices from the exchange itself: India (NSE), Taiwan (TWSE, TPEx), Brazil (B3), Poland (GPW), Russia (MOEX), Hong Kong (HKEX) and Sri Lanka (CSE). US listings have no daily price source on the site yet.

Sources: company history from Wikidata, SEC EDGAR, GLEIF and the site's own tables; results releases from SEC EDGAR (Form 8-K, item 2.02); annual reports from SEC EDGAR (10-K, 20-F, 40-F); stock splits from SEC filings; insider buying and large selling from SEC Forms 4 and 5; notable 8-k events from SEC EDGAR (Form 8-K); layoffs from State WARN notices and SEC 8-K item 2.05. Recurring events go back 15 years; the company's history is shown in full. Dividends appear when the amount per share changed; insider selling when a month's sales reach $10 million or 0.01% of the company.